June 2026, Coherent Market Insights: Amsterdam's RAI Convention Centre was host to one of the most consequential gatherings in global healthcare — HLTH Europe 2026. Held from 15 to 18 June, Europe's #1 healthcare innovation event brought together more than 400 speakers, 350+ sponsors, and delegates from over 65 countries, with one in three attendees operating at the C-suite level. Coherent Market Insights (CMI) was proud to participate as an Official Partner, using the platform to advance industry dialogue and launch its most comprehensive research offering to date: the GLP-1 Market Analysis (2026–2033) Executive Summary Report.
Where the Entire Healthcare Ecosystem Convenes
HLTH Europe 2026 is more than a conference. It is a deliberate collision of perspectives — pharma and life sciences leaders alongside health system executives, government policymakers alongside digital health disruptors, venture investors alongside startup founders. This year's edition was structured around transformative programming tracks including the AI @ HLTH Zone, the Global Pharma Summit, the Health Transformation Summit, HLTH.rad (a dedicated radiology and imaging track), an Interoperability Spotlight, and a competitive Startup Pitch arena. The breadth of the agenda reflected what has become the defining characteristic of HLTH: no single constituency owns the conversation.
The energy on the floor matched the ambition. Attendees from organisations including Siemens Healthineers, MSD, and SAS described the event in striking terms — "Easily the best event we've ever been to," said one delegate, while another called it "one of my absolute best conference days ever." These are not the reactions of people who attended out of obligation. They are the reactions of an ecosystem that recognises it is at a turning point.
GLP-1: The Market That Defined the Conversation
Few topics generated more sustained interest at HLTH Europe 2026 than the rapidly evolving landscape of GLP-1 receptor agonist therapies. Against this backdrop, CMI offered its GLP-1 Market Analysis (2026–2033) — a data-driven deep dive that arrived at precisely the right moment.
The headline numbers tell a compelling story. The global GLP-1 market was valued at approximately USD 53.5 billion in 2025, with projections pointing to nearly USD 102.4 billion by 2031, expanding at a CAGR of 11.6%. Looking further ahead, the broader GLP-1 receptor agonist market is expected to surpass USD 311.6 billion by 2033 — representing close to a 2.2x expansion of the industry over the forecast period.
"What we're seeing in the GLP-1 space isn't just incremental growth — it's a structural shift in how chronic metabolic conditions are managed," said Raj Shah, CEO and Founder, Coherent Market Insights. "The combination of unmet clinical need, rapid pipeline innovation, and expanding payer support is creating a rare alignment of demand and capability."
The scale of that unmet need is hard to overstate. More than 589 million adults worldwide are living with diabetes, and over one billion adults are classified as obese — a population whose unmet therapeutic needs have, until recently, been significantly underserved by available treatment options.
Beyond the Hype: Why This Growth Is Structural
What distinguishes the current moment in the GLP-1 market from previous growth cycles is the convergence of multiple tailwinds that rarely align simultaneously. Expanding treatment guidelines, growing reimbursement coverage in key markets, and the rise of telehealth-enabled prescribing have removed many of the access barriers that previously constrained uptake.
"We're at an inflection point where epidemiology, policy, and innovation are moving in the same direction at the same time," observed Raj Shah. "That alignment is rarely seen at this scale, and it's a major reason why we expect this category to remain one of the most closely watched in healthcare investment over the next decade."
This observation found resonance across multiple conversations at HLTH Europe, where discussions around digital prescribing platforms, payer engagement strategies, and real-world outcomes data repeatedly circled back to GLP-1 therapies as a case study in how structural healthcare transformation actually happens — not through a single breakthrough, but through the patient accumulation of clinical evidence, policy reform, and commercial infrastructure.
The Next Wave: Convenience, Durability, Accessibility
Pipeline innovation within the GLP-1 space is no longer solely focused on efficacy. The next generation of therapies is being designed around patient experience with oral formulations, longer-acting injectable agents, and dual and triple agonist molecules that address multiple metabolic pathways simultaneously.
"The next wave of GLP-1 innovation won't just be about efficacy but it will be about convenience, durability, and accessibility," noted Raj Shah. "Oral formulations and longer-acting agents could meaningfully widen the patient pool that's willing and able to start treatment."
"For investors, the question is no longer whether GLP-1 therapies will reshape metabolic health — it's which companies are best positioned to scale responsibly as access expands," said Raj Shah. The report's analysis of competitive positioning, pipeline strength, and strategic M&A activity provides a structured framework for answering exactly that question.
CMI's Commitment to Evidence-Driven Healthcare Dialogue
CMI's partnership with HLTH Europe 2026 reflects a broader conviction: that meaningful change in healthcare requires not just innovation, but the research analysis to evaluate, contextualise, and communicate that innovation to the people who need to act on it.
"Partnering with HLTH Europe 2026 is a natural extension of CMI's commitment to catalysing meaningful change in the global healthcare landscape," said Raj Shah. "We look forward to contributing to conversations that will define the next chapter of health innovation and to connecting with change-makers from across the world."
As the global healthcare community looks toward the challenges and opportunities ahead, CMI remains committed to equipping decision-makers in pharma, investment, policy, and beyond with the rigorous, evidence-based intelligence they need to act with confidence.
The GLP-1 Market Analysis (2026–2033) Summary Report is available via Coherent Market Insights. For business inquiries and getting access to GLP-1 Market Analysis (2026–2033) Summary Report, contact: sales@coherentmarketinsights.com
About HLTH Europe 2026
HLTH Europe is the continent’s preeminent health innovation conference, bringing together the brightest minds in healthcare from startups, established enterprises, government bodies, and non-profit organisations. The 2026 edition was held from 15 to 18 June 2026 and featured keynote addresses, curated networking, investment forums, and immersive workshops designed to accelerate real-world health transformation.
About Coherent Market Insights
Coherent Market Insights (CMI) is a global market intelligence and growth consulting firm delivering data-driven insights. Headquartered in India, with offices in the U.S, and UK, and strategic partnerships across the Japan, South Korea, and Australia, CMI supports clients in over 32 countries with 300+ full-time consultants and a global network of more than 120 contract consultants across 24 countries.
Contact Us